1. Academic Validation
  2. SLC35D3 promotes white adipose tissue browning to ameliorate obesity by NOTCH signaling

SLC35D3 promotes white adipose tissue browning to ameliorate obesity by NOTCH signaling

  • Nat Commun. 2023 Nov 23;14(1):7643. doi: 10.1038/s41467-023-43418-5.
Hongrui Wang # 1 Liang Yu # 1 Jin'e Wang # 2 Yaqing Zhang 2 Mengchen Xu 1 Cheng Lv 1 Bing Cui 1 Mengmeng Yuan 1 Yu Zhang 1 Yupeng Yan 1 Rutai Hui 1 Yibo Wang 3
Affiliations

Affiliations

  • 1 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • 2 College of Basic Medical Sciences, China Three Gorges University, Yichang, Hubei, China.
  • 3 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. yibowang@hotmail.com.
  • # Contributed equally.
Abstract

White adipose tissue browning can promote lipid burning to increase energy expenditure and improve adiposity. Here, we show that Slc35d3 expression is significantly lower in adipose tissues of obese mice. While adipocyte-specific Slc35d3 knockin is protected against diet-induced obesity, adipocyte-specific Slc35d3 knockout inhibits white adipose tissue browning and causes decreased energy expenditure and impaired Insulin sensitivity in mice. Mechanistically, we confirm that SLC35D3 interacts with the NOTCH1 extracellular domain, which leads to the accumulation of NOTCH1 in the endoplasmic reticulum and thus inhibits the NOTCH1 signaling pathway. In addition, knockdown of Notch1 in mouse inguinal white adipose tissue mediated by orthotopic injection of AAV8-adiponectin-shNotch1 shows considerable improvement in obesity and glucolipid metabolism, which is more pronounced in adipocyte-specific Slc35d3 knockout mice than in knockin mice. Overall, in this study, we reveal that SLC35D3 is involved in obesity via NOTCH1 signaling, and low adipose SLC35D3 expression in obesity might be a therapeutic target for obesity and associated metabolic disorders.

Figures
Products